NEW YORK (GenomeWeb) – MDx Health said today it has signed an agreement with The Netherlands' University Erasmus Medical Center (Erasmus MC) giving it exclusive worldwide rights to the use of a set of bladder cancer methylation biomarkers for clinical assay development in either the LDT or IVD setting.

The company also announced that it plans to present new top-line data on the liquid biopsy bladder cancer test it is developing with these markers at the World Congress on Urological Research meeting in September.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.